Structural and functional interaction of (±)-2-(N-tert-butylamino)- 3′-iodo-4′-azidopropiophenone, a photoreactive bupropion derivative, with nicotinic acetylcholine receptors

Neurochemistry International

Volumn 61, Issue 8, 2012, Pages 1433-1441

  Arias, Hugo R ^a   Feuerbach, Dominik ^b   Targowska Duda, Katarzyna M ^c   Aggarwal, Shaili ^d   Lapinsky, David J ^d   Jozwiak, Krzysztof ^c  

^a California Northstate University   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d DUQUESNE UNIVERSITY   (United States)

Author keywords

Antidepressants; Bupropion; Conformational states; Nicotinic acetylcholine receptors; Noncompetitive antagonists; Photoreactive ligand

Indexed keywords

2 (N TERT BUTYLAMINO) 3' IODO 4' AZIDOPROPIOPHENONE; AMFEBUTAMONE; CYTISINE; EPIBATIDINE; ION CHANNEL; NICOTINIC RECEPTOR; SERINE; UNCLASSIFIED DRUG; VALINE;

ARTICLE; BINDING AFFINITY; BINDING SITE; CALCIUM TRANSPORT; CONFORMATIONAL TRANSITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SIMULATION;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AZIDES; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; BUPROPION; CALCIUM SIGNALING; CELL LINE, TUMOR; HUMANS; HYDROGEN BONDING; MODELS, CHEMICAL; MOLECULAR STRUCTURE; MUSCLE, SKELETAL; NEUROMUSCULAR JUNCTION; PHOTOCHEMISTRY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; PYRIDINES; RECEPTORS, NICOTINIC; RHABDOMYOSARCOMA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TOBACCO USE CESSATION PRODUCTS;

EID: 84870299499     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2012.10.011     Document Type: Article

References (30)

1. H.R. Arias Ligand-gated ion channel receptor superfamilies H.R. Arias, Biological and Biophysical Aspects of Ligand-Gated Ion Channel Receptor Superfamilies 2006 Research Signpost Kerala, India 1 25
2. H.R. Arias Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int. J. Biochem. Cell Biol. 41 2009 2098 2108
3. H.R. Arias Molecular interaction of bupropion with nicotine acetylcholine receptors J. Pediatr. Biochem. 1 2010 185 197
4. H.R. Arias, P. Bhumireddy, and C. Bouzat Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors Int. J. Biochem. Cell Biol. 38 2006 1254 1276
5. H.R. Arias, F. Gumilar, A. Rosenberg, K.M. Targowska-Duda, D. Feuerbach, K. Jozwiak, R. Moaddel, I.W. Wainer, and C. Bouzat Interaction of bupropion with muscle-type nicotinic acetylcholine receptors in different conformational states Biochemistry 48 2009 4506 4518
6. H.R. Arias, D. Feuerbach, P. Bhumireddy, and M.O. Ortells Inhibitory mechanisms and binding site locations for serotonin selective reuptake inhibitors on nicotinic acetylcholine receptors Int. J. Biochem. Cell Biol. 42 2010 712 724
7. H.R. Arias, E.A. McCardy, E.Z. Bayer, M.J. Gallagher, and M.B. Blanton Allosterically linked noncompetitive antagonist binding sites in the resting nicotinic acetylcholine receptor ion channel Arch. Biochem. Biophys. 403 2002 121 131
8. H.R. Arias, J.R. Trudell, E.Z. Bayer, B. Hester, E.A. McCardy, and M.B. Blanton Noncompetitive antagonist binding sites in the Torpedo nicotinic acetylcholine receptor ion channel. Structure-activity relationship studies using adamantane derivatives Biochemistry 42 2003 7358 7370
9. M.L. Bondarev, T.S. Bondareva, R. Young, and R.A. Glennon Behavioral and biochemical investigations of bupropion metabolites Eur. J. Pharmacol. 474 2003 85 93
10. F.I. Carroll, B.E. Blough, S.W. Mascarella, H.A. Navarro, J.B. Eaton, R.J. Lukas, and M.I. Damaj Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation J. Med. Chem. 53 2010 2204 2214
11. 50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
12. M.I. Damaj, F.I. Carroll, J.B. Eaton, H.A. Navarro, B.E. Blough, S. Mirza, R.J. Lukas, and B.R. Martin Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors Mol. Pharmacol. 66 2004 675 682
13. M.I. Damaj, S.D. Grabus, H.A. Navarro, R.E. Van, J.A. Warner, L.S. King, J.L. Wiley, B.E. Blough, R.J. Lukas, and F.I. Carroll Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice J. Pharmacol. Exp. Ther. 334 2010 1087 1095
14. J.D. Fryer, and R.J. Lukas Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine J. Pharmacol. Exp. Ther. 288 1999 88 92
15. E. Gasteiger, A. Gattiker, C. Hoogland, I. Ivanyi, R.D. Appel, and A. Bairoch ExPASy: the proteomics server for in-depth protein knowledge and analysis Nucleic Acids Res. 31 2003 3784 3788
16. F. Gumilar, H.R. Arias, G. Spitzmaul, and C. Bouzat Molecular mechanism of inhibition of nicotinic acetylcholine receptors by tricyclic antidepressants Neuropharmacology 45 2003 964 976
17. H.M. Kamens, S.H. Stephens, and M.A. Ehringer Human genetic studies of CHRN genes H.R. Arias, Pharmacology of Nicotinic Acetylcholine Receptors from the Basic and Therapeutic Perspectives 2011 Research Signpost Kerala, India 19 43
18. 125I]-iodo-4′-azidopropiophenone: a dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban Bioorg. Med. Chem. Lett. 22 2012 523 526
19. R.J. Lukas, A.Z. Muresan, M.I. Damaj, B.E. Blough, X. Huang, H.A. Navarro, S.W. Mascarella, J.B. Eaton, S.K. Marxer-Miller, and F.I. Carroll Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation J. Med. Chem. 53 2010 4731 4748
20. S. Michelmore, K. Croskery, J. Nozulak, D. Hoyer, R. Longato, A. Weber, R. Bouhelal, and D. Feuerbach Study of the calcium dynamics of the human α4β2, α3β4 and α1β1γδ nicotinic acetylcholine receptors Naunyn-Schmiedebergs Arch. Pharmacol. 366 2002 235 245
21. N.S. Millar, and I. Denholm Nicotinic acetylcholine receptors: targets for commercially important insecticides Invert. Neurosci. 7 2007 53 66
22. A. Miyazawa, Y. Fujiyoshi, and N. Unwin Structure and gating mechanism of the acetylcholine receptor pore Nature 423 2003 949 955
23. M.A. Moore, and M.P. McCarthy Snake venom toxins, unlike smaller antagonists, appear to stabilize a resting state conformation of the nicotinic acetylcholine receptor Biochim. Biophys. Acta 1235 1995 336 342
24. O.R. Pagán, V.A. Eterović, M. García, D. Vergne, C.M. Basilio, A.D. Rodríguez, and R.M. Hann Cembranoid and long-chain alkanol sites on the nicotinic acetylcholine receptor and their allosteric interaction Biochemistry 40 2001 11121 11130
25. 125I]-SADU-3-72 Biochemistry 51 2012 2425 2435
26. A. Santamaría, and H.R. Arias Neurochemical and behavioral effects elicited by bupropion and diethylpropion in rats Behav. Brain Res. 211 2010 132 139
27. J.E. Slemmer, B.R. Martin, and M.I. Damaj Bupropion is a nicotinic antagonist J. Pharmacol. Exp. Ther. 295 2000 321 327
28. J.D. Thompson, D.G. Higgins, and T.J. Gibson CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice Nucleic Acids Res. 22 1994 4673 4680
29. N. Unwin Refined structure of the nicotinic acetylcholine receptor at 4 Å resolution J. Mol. Biol. 346 2005 967 989
30. W. Weber, T. David-Pfeuty, and J.-P. Changeux Regulation of binding properties of the nicotinic receptor protein by cholinergic ligands in membrane fragments from Torpedo marmorata Proc. Natl. Acad. Sci. USA 72 1975 3443 3447